Prevention & lipidsSecondary analysis
The potential benefit of statin prescription based on prediction of treatment responsiveness in older individuals: an application to the PROSPER randomized controlled trial
- Secondary analysis of the PROSPER randomised trial
- derivation and internal-external validation of a treatment-responsiveness prediction model
Authors' conclusion
Pravastatin prescription based on predicted responsiveness may have an encouraging potential for cardiovascular prevention.
Study context
- Population
- Individuals aged 70–82 years with a history of, or risk factors for, vascular diseases
- Participants
- 2,913 / 2,891 / 2,925 / 2,890
- Comparison
- Three pravastatin prescription strategies vs placebo
- Placebon = 2,913reference
- Pravastatin to alln = 2,891
- Elevated vascular riskn = 2,925
- Favourable prediction of treatment responsen = 2,890
- Primary endpoint
- Coronary death, non-fatal MI, and fatal or non-fatal stroke
Primary result
As reported in the abstract
Coronary death, non-fatal MI, or fatal or non-fatal stroke, per 10 000 person-years
Each group vs placeboAbsolute difference, events per 10 000 person-years (95% CI)
Pravastatin to all
−78(−144 to −12)
Elevated vascular risk
−66(−114 to −18)
Favourable prediction of treatment response
−103(−162 to −44)
Original publication
The potential benefit of statin prescription based on prediction of treatment responsiveness in older individuals: an application to the PROSPER randomized controlled trial. Eur J Prev Cardiol. Published 12 December 2023. doi:10.1093/eurjpc/zwad383
Summarised from the published abstract; every number is checked against it